NK-cell immunotherapy was developed for oncology, but may take off elsewhere

A story on the limits of current immunotherapy in cancer, new developments and pivoting cancer treatments to other diseases, highlighting a great publication on idiopathic pulmonary fibrosis

I’ve had a long-standing frustration with how narrow cancer immunotherapy currently is. There are a million ways immune cells take out cancer cells and cancer cells subdue the immune system. This strongly contrast with immunotherapy, which almost exclusively revolves around inhibiting CTLA-4 and PD-1/PD-L1. True, drugs such as pembrolizumab which inhibi…